Pancreatic Cancer Research

ResearcherLinköping UniversityNo recent work listed

Winson Y. Cheung

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3679-4290; OpenAlex author ID A5039850848. Sources: OpenAlex.

Their work

Papers
14 (first author 3, last author 5)
Trials
0
Grants
0
Labs led
2
Collaborators
25
Papers, trials and grants by year

2017: 3 papers · 2018: 4 papers · 2019: 3 papers · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper

Papers 14

  1. Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: a target trial emulation using real-world data. Co-author DOI 10.1016/j.annepidem.2022.12.005↗
  2. Changing Rates of Goals of Care Designations in Patients With Advanced Pancreatic Cancer During a Multifactorial Advanced Care Planning Initiative: A Real-Worl… Co-author DOI 10.1200/op.21.00649↗
  3. Prognostic Significance of Disease Control at 12 Weeks in Patients With Advanced Pancreatic Cancer Receiving FOLFIRINOX as First-line Chemotherapy. Last author DOI 10.1097/coc.0000000000000856↗
  4. Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer. Co-author DOI 10.5306/wjco.v12.i9.787↗
  5. Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000500↗
  6. Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000625↗
  7. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review. First author DOI 10.1177/1758835919850367↗
  8. A real-world, population-based study of patterns of referral, treatment, and outcomes for advanced pancreatic cancer. Last author DOI 10.1002/cam4.1841↗
  9. Primary Care Versus Oncology-Based Surveillance Following Adjuvant Chemotherapy in Resected Pancreatic Cancer. Last author DOI 10.1007/s12029-017-9988-8↗
  10. A population-based analysis of urban-rural disparities in advanced pancreatic cancer management and outcomes. Last author DOI 10.1007/s12032-018-1173-9↗
  11. A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma. First author DOI 10.1155/2018/1863535↗
  12. Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX. Last author DOI 10.1097/coc.0000000000000193↗
  13. Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospect… Co-author DOI 10.1097/coc.0000000000000205↗
  14. Evolving treatment landscape for early and advanced pancreatic cancer. First author DOI 10.4251/wjgo.v9.i7.281↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Atul Batra · 2 shared papers, 2021 · strength 0.41
  2. Sharlene Gill · 4 shared papers, 2017–2019 · strength 0.36
  3. Jennifer L. Spratlin · 2 shared papers, 2019–2022 · strength 0.29
  4. Daniel John Renouf · 3 shared papers, 2017–2019 · strength 0.26
  5. Erica S. Tsang · 2 shared papers, 2019 · strength 0.20
  6. Devon J. Boyne · 1 shared paper, 2023 · strength 0.19
  7. Darren R. Brenner · 1 shared paper, 2023 · strength 0.19
  8. Miguel Ángel Hernán · 1 shared paper, 2023 · strength 0.19
  9. Nils O. Elander · 1 shared paper, 2021 · strength 0.19
  10. Hakon Blomstrand · 1 shared paper, 2021 · strength 0.19
  11. Matthew Anaka · 1 shared paper, 2022 · strength 0.19
  12. Hagen Fritz Kennecke · 2 shared papers, 2017–2019 · strength 0.18
  13. Irene S. Yu · 1 shared paper, 2018 · strength 0.17
  14. Maria Yi Ho · 2 shared papers, 2017 · strength 0.16
  15. Sally C. M. Lau · 1 shared paper, 2017 · strength 0.15
  16. Thomas D. Canale · 1 shared paper, 2018 · strength 0.14
  17. Salah Eddin Al-Batran · 1 shared paper, 2019 · strength 0.12
  18. Guido Giordano · 1 shared paper, 2019 · strength 0.12
  19. George Kim · 1 shared paper, 2019 · strength 0.12
  20. Elena Gabriela Chiorean · 1 shared paper, 2019 · strength 0.12
  21. Haider H. Samawi · 1 shared paper, 2018 · strength 0.12
  22. Christina Kim · 1 shared paper, 2019 · strength 0.11
  23. Omar Mohammed Abdel-Rahman · 1 shared paper, 2018 · strength 0.11
  24. Hui‐Li Wong · 1 shared paper, 2019 · strength 0.10
  25. Renata D’Alpino Peixoto · 1 shared paper, 2017 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.